William Blair analyst Ryan Daniels has maintained their bullish stance on MD stock, giving a Buy rating on February 3.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ryan Daniels has given his Buy rating due to a combination of factors that highlight improving fundamentals and earnings quality at Pediatrix Medical Group. Although fourth-quarter revenue and EBITDA were mixed versus consensus, management’s 2026 profit outlook implies healthier margins supported by a streamlined portfolio and completion of exits from noncore businesses, which should translate into more predictable profitability.
Daniels also points to a more advantageous payer mix, rising patient acuity in core hospital-based neonatology operations, and better cash collections enabled by the hybrid revenue cycle model as key supports for future earnings. While patient volumes are under pressure from historically low U.S. birth rates, he views current results as aligned with sector trends and believes efficiency gains and pricing dynamics can offset volume headwinds, justifying a positive stance on the shares.
In another report released on February 3, TipRanks – Anthropic also reiterated a Buy rating on the stock with a $24.50 price target.